95
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Low dose stereotactic irradiation and dexamethasone in primary cerebral light chain deposition disease (LCDD)

, ORCID Icon, , , , , , , , & show all
Pages 2267-2271 | Received 10 Jan 2021, Accepted 08 Mar 2021, Published online: 31 Mar 2021

References

  • Gallo GR, Feiner HD, Chuba JV, et al. Characterization of tissue amyloid by lmmunofluorescence microscopy. Clin Immunol Immunopathol. 1986;39(3):479–490.
  • Randall RE, Williamson WC, Jr., Mullinax F, et al. Manifestations of systemic light chain deposition. Am J Med. 1976;60(2):293–299.
  • Bullmann C. Hyponatriämie. Arzneiverordnung in Der Praxis (AVP). 2016;43(4):188–194.
  • Lapa C, Schreder M, Schirbel A, et al. [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - comparison to [18F]FDG and laboratory values. Theranostics. 2017;7(1):205–212.
  • Herhaus P, Lipkova J, Lammer F, et al. CXCR4-targeted positron emission tomography imaging of central nervous system B-cell lymphoma. J Nucl Med. 2020;61(12):1765–1771.
  • Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: World Health Organization Classification of Tumours; 2017. 585. p. International Agency for Research on Cancer.
  • Skardelly M, Pantazis G, Bisdas S, et al. Primary cerebral low-grade B-cell lymphoma, monoclonal immunoglobulin deposition disease, cerebral light chain deposition disease and “aggregoma”: an update on classification and diagnosis. BMC Neurol. 2013;13:107.
  • Sanders PW, Herrera GA. Monoclonal immunoglobulin light chain-related renal diseases. Semin Nephrol. 1993;13(3):324–341.
  • Buxbaum J, Gallo G. Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light- and heavy-chain deposition diseases. Hematol Oncol Clin North Am. 1999;13(6):1235–1248.
  • Jimenez-Zepeda VH. Light chain deposition disease: novel biological insights and treatment advances. Int J Lab Hematol. 2012;34(4):347–355.
  • Boulter TD, Sadaka A, Nakawah MO, et al. Primary central nervous system lymphoma with light chain deposition disease (aggregoma). J Neuroophthalmol. 2018;38(2):195–197.
  • Mercado JJ, Markert JM, Meador W, Chapman P, et al. Primary CNS nonamyloidogenic light chain deposition disease: case report and brief review. Int J Surg Pathol. 2017;25(8):755–760.
  • Popović M, Tavćar R, Glavac D, et al. Light chain deposition disease restricted to the brain: the first case report. Hum Pathol. 2007;38(1):179–184.
  • Stratta P, Gravellone L, Cena T, et al. Renal outcome and monoclonal immunoglobulin deposition disease in 289 old patients with blood cell dyscrasias: a single center experience. Crit Rev Oncol Hematol. 2011;79(1):31–42.
  • Went P, Ascani S, Strom E, et al. Nodal marginal-zone lymphoma associated with monoclonal light-chain and heavy-chain deposition disease. Lancet Oncol. 2004;5(6):381–383.
  • Fischer L, Korfel A, Stoltenburg-Didinger G, et al. A 19-year-old male with generalized seizures, unconsciousness and a deviation of gaze. Brain Pathol. 2006;16(2):185–186.
  • Vital A, Ellie E, Loiseau H. A 61-year-old man with instability of gait and right hand clumsiness. Brain Pathol. 2010;20(1):273–274.
  • Menke JR, Jentoft ME, Dogan A, et al. Periventricular white matter immunoglobulin lambda light chain deposition disease diagnosed by proteomic analysis. Acta Neuropathol. 2012;124(2):293–295.
  • Pantazis G, Psaras T, Krope K, et al. Cerebral low-grade lymphoma and light chain deposition disease: exceedingly high igg levels in the cerebrospinal fluid as a diagnostic clue. Clin Neuropathol. 2010;29(6):378–383.
  • Heß K, Purrucker J, Hegenbart U, et al. Cerebral amyloidoma is characterized by B-cell clonality and a stable clinical course. Brain Pathol. 2018;28(2):234–239.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.